• Adjusted gross profit up 14% driven by an excellent performance by Commercial Medicines and eight months’ contribution from Quantum
  • Good growth and contract wins in Africa and Asia Pacific region
  • Strong performance from Quantum with integration progressing to plan; £1.1m in cost synergies already realised
  • Adjusted EPS up 10% to 45.4p (2017: 41.3p)
  • Good cash flow performance with cash generated from operations up 17% to £64.1m (2017: £54.7m)
  • Full year dividend increased 12% to 5.6p (2017: 5.0p)
  • Profit before income tax of £35.9m (2017: £14.1m)